论文部分内容阅读
目的观察凯西莱注射液对甲状腺功能亢进症合并药物性肝损伤的临床疗效。方法选择甲状腺功能亢进症(Graves病)合并肝损伤患者102例,随机分为对照组和治疗组。对照组应用一般保肝药物,治疗组在对照组基础上加用凯西莱注射液。两组均在治疗前、治疗后1、2、3周分别检测肝功能观察疗效。结果两组在治疗21 d后丙氨酸氨基转移酶下降为(46±16)U/L,门冬氨酸氨基转移酶下降为(45±12)U/L(P<0.01),治疗组氨基转移酶恢复时间较对照组明显缩短(P<0.05)。结论凯西莱可明显改善Graves病合并肝损伤,缩短病程。
Objective To observe the clinical effect of Kesilai injection on hyperthyroidism complicated with drug-induced liver injury. Methods 102 cases of hyperthyroidism (Graves’ disease) with liver injury were randomly divided into control group and treatment group. The control group of general liver protection drugs, the treatment group in the control group based on the use of Kesilai injection. Both groups were observed before and after treatment, 1,2,3 weeks of liver function were observed efficacy. Results The alanine aminotransferase decreased to (46 ± 16) U / L and aspartate aminotransferase decreased to (45 ± 12) U / L after 21 days of treatment in both groups (P <0.01) Aminotransferase recovery time was significantly shorter than the control group (P <0.05). Conclusion Kesilai can significantly improve Graves’ disease with liver injury and shorten the course of the disease.